C-PQV4X-tosis
mitochondrial therapeutics, VDAC1 modulation, precision biomarkers
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-PQV4
C-PQV4C-PQV4mitochondrial therapeutics, VDAC1 modulation, precision biomarkers
0-100 chain-logic scale · 15 dimensions · scored on public evidence
X-tosis mitochondrial therapeutics, VDAC1 modulation, precision biomarkers
X-tosis is a precision-medicine platform company developing first-in-class mitochondrial therapeutics to prevent neuronal loss. Its VDAC1-modulating compounds are designed to restore mitochondrial function, reduce inflammation, and prevent neuronal death. The company focuses on neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, ALS, and related conditions.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
X-tosis — Early mechanism · Lower middle. Derived deterministically from 2 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic